Data gathered: May 28
AI Stock Analysis - Arcutis Biotherapeutics (ARQT)
Analysis generated December 16, 2024. Powered by Chat GPT.
Arcutis Biotherapeutics is a leading biopharmaceutical company dedicated to developing novel treatments for dermatological conditions. With a strong focus on innovation and patient-centric care, the company aims to address unmet clinical needs in dermatology through its robust pipeline of drug candidates. Founded on scientific rigor and clinical expertise, Arcutis Biotherapeutics has been making strides in the therapeutic landscape, particularly in conditions like psoriasis and atopic dermatitis.
Stock Alerts - Arcutis Biotherapeutics (ARQT)
 |
Arcutis Biotherapeutics | May 24 Insider Alert: Heron Patrick J is continuing buying shares |
|
Arcutis Biotherapeutics | May 21 Insider Alert: Edwards Larry Todd is selling shares |
|
Arcutis Biotherapeutics | May 20 Insider Alert: Heron Patrick J is continuing buying shares |
|
Arcutis Biotherapeutics | May 14 Insider Alert: Heron Patrick J is buying shares |
Download our app to get future alerts delivered in real-time.
Alternative Data for Arcutis Biotherapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 4 | Sign up | Sign up | Sign up |
| Sentiment | 88 | Sign up | Sign up | Sign up |
| Webpage traffic | 16,000 | Sign up | Sign up | Sign up |
| Employee Rating | 88 | Sign up | Sign up | Sign up |
| Google Trends | 17 | Sign up | Sign up | Sign up |
| Patents | 36 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 23 | Sign up | Sign up | Sign up |
| Facebook Followers | 2,448 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 109 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 2,427 | Sign up | Sign up | Sign up |
| Twitter Followers | 593 | Sign up | Sign up | Sign up |
| Twitter Mentions | 20 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 48 | Sign up | Sign up | Sign up |
| Linkedin Employees | 368 | Sign up | Sign up | Sign up |
About Arcutis Biotherapeutics
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases.
| Price | $13.58 |
| Target Price | Sign up |
| Volume | 1,310,000 |
| Market Cap | $1.67B |
| Year Range | $8.31 - $17.29 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
Arcutis Biotherapeutics’ (ARQT) Buy Rating Reiterated at Needham & Company LLCMay 25 - ETF Daily News |
 |
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Receives $18.80 Consensus Target Price from AnalystsMay 23 - ETF Daily News |
Arcutis Biotherapeutics, Inc. Announces the U.S. Food and Drug Administration Approves the Supplemental New Drug Application for ZORYVE®? (roflumilast) Topical Foam 0.3% for the Treatment of Plaque Psoriasis of the ScalpMay 22 - Finnhub |
|
|
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Shares Sold by Deutsche Bank AGMay 19 - ETF Daily News |
|
Northern Trust Corp Purchases 54,541 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)May 16 - ETF Daily News |
Arcutis Biotherapeutics, Inc. Announces the Publication of 14 Consensus Statements from the Genital Psoriasis Wellness ConsortiumMay 14 - Finnhub |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q1 '25 | 66M | 8.8M | 57M | -25M | 0 | -0.200 |
| Q4 '24 | 71M | 6.9M | 64M | -11M | -4.5M | -0.090 |
| Q3 '24 | 45M | 5.5M | 39M | -42M | -33M | -0.330 |
| Q2 '24 | 31M | 3.5M | 27M | -52M | -44M | -0.420 |
| Q1 '24 | 50M | 3.3M | 46M | -35M | -31M | -0.320 |
Insider Transactions View All
| Heron Patrick J filed to buy 22,534 shares at $13.7. May 23 '25 |
| Edwards Larry Todd filed to sell 183,104 shares at $14.1. May 20 '25 |
| Heron Patrick J filed to buy 17,494 shares at $13.6. May 19 '25 |
| Heron Patrick J filed to buy 14,974 shares at $13.8. May 15 '25 |
| Heron Patrick J filed to buy 8,674 shares at $13.8. May 15 '25 |
Similar companies
Read more about Arcutis Biotherapeutics (ARQT) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Arcutis Biotherapeutics?
The Market Cap of Arcutis Biotherapeutics is $1.67B.
What is the current stock price of Arcutis Biotherapeutics?
Currently, the price of one share of Arcutis Biotherapeutics stock is $13.58.
How can I analyze the ARQT stock price chart for investment decisions?
The ARQT stock price chart above provides a comprehensive visual representation of Arcutis Biotherapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Arcutis Biotherapeutics shares. Our platform offers an up-to-date ARQT stock price chart, along with technical data analysis and alternative data insights.
Does ARQT offer dividends to its shareholders?
As of our latest update, Arcutis Biotherapeutics (ARQT) does not offer dividends to its shareholders. Investors interested in Arcutis Biotherapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Arcutis Biotherapeutics?
Some of the similar stocks of Arcutis Biotherapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.